medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/2079-701X-2019-4-52-60medsovet-3116Research ArticleОСЛОЖНЕНИЯ САХАРНОГО ДИАБЕТАCOMPLICATIONS OF DIABETESБолевая диабетическая полинейропатия: от клинических рекомендаций к повседневной практикеPainful diabetic polyneuropathy: from clinical guidelines to daily practiceХрамилинВ. Н.KhramilinV. N.

Храмилин Владимир Николаевич - кандидат медицинских наук, кафедра эндокринологии и диабетологии факультета дополнительного профессионального образования.

117997, Москва, ул. Островитянова, д. 1; тел.: +7(495) 48394-44

Khramilin Vladimir Nikolaevich - Cand. of Sci.(Med.), Chair of Endocrinology and Diabetology, Faculty of Additional Professional Education.

117997, Moscow, Ostrovityanova St., 1; Tel.: +7(495) 483-94-44

Khramilin_RGMU@mail.ruДемидоваИ. Ю.DemidovaI. Yu.

Демидова Ирина Юрьевна - доктор медицинских наук, профессор, зав. кафедрой эндокринологии и диабетологии факультета дополнительного профессионального образования.

117997, Москва, ул. Островитянова, д. 1; тел.: +7(495) 483-94-44

Demidova Irina Yurievna - Dr. of Sci.(Med.), Professor, Head of Chair of Endocrinology and Diabetology, Faculty of Additional Professional Education.

117997, Moscow, Ostrovityanova St., 1; Tel.: +7(495) 483-94-44

ЗавьяловА. Н.ZavialovA. N.

Завьялов Александр Николаевич - врач-эндокринолог, аспирант, старший лаборант кафедры эндокринологии и диабетологии факультета дополнительного профессионального образования.

117997, Москва, ул. Островитянова, д. 1; тел.: +7(495) 483-94-44

Zavyalov Aleksandr Nikolaevich - Cand. of Sci.(Med.), Chair of Endocrinology and Diabetology, Faculty of Additional Professional Education.

117997, Moscow, Ostrovityanova St., 1; Tel.: +7(495) 483-94-44

Федеральное государственное бюджетное образовательное учреждение высшего образования «Российский национальный исследовательский медицинский университет имени Н.И. Пирогова» Министерства здравоохранения Российской ФедерацииРоссияFederal State Budgetary Educational Institution of Higher Education «Russian National Research Medical University named after N.I. Pirogov» of the Ministry of Health of the Russian FederationRussian Federation201920082019045260Copyright © Храмилин В.Н., Демидова И.Ю., Завьялов А.Н., 20192019Храмилин В.Н., Демидова И.Ю., Завьялов А.Н.Khramilin V.N., Demidova I.Y., Zavialov A.N.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/3116

Диабетическая полинейропатия (ДПН) и нейропатическая боль в значительной мере ухудшают качество жизни пациентов с сахарным диабетом. Клинические рекомендации часто не рассматривают альтернативные варианты терапии. Цели лечения болевой ДПН должны быть индивидуализированы. Выбор препарата для лечения болевой ДПН зависит от эффективности, профиля безопасности и существующей или потенциальной коморбидной патологии.

Diabetic neuropathy and neuropathic pain worsen the quality of life of patients with diabetes. Clinical recommendations are not uniform and, often, do not consider alternative treatment options. The goals of treatment for diabetic painful neuropathy should be individualized. The choice of drug for the treatment of painагд DPN depends on the effectiveness, safety profile and existing or potential comorbid pathology.

сахарный диабетдиабетическая полинейропатиянейропатическая больDiabetic polyneuropathyneuropathic paindiabetes mellitusReferencesДавыдов О.С., Яхно Н.Н., Кукушкин М.Л. и соавт. Невропатическая боль. Клинические рекомендации по диагностике и лечению. РОИБ. М., 2018:1-88.Davydov O.S., Yakhno N.N., Kukushkin M.L., et al. Neuropathic pain. Clinical guidelines for diagnosis and treatment. Russian Association for the Study of Pain M., 2018: 1-88. (In Russ).Дедов И.И., Омельяновский В.В., Шестакова М.В., Авксентьева М.В., Игнатьева В.И. Сахарный диабет как экономическая проблема в Российской Федерации. Сахарный диабет. 2016;19(1):30-43.Dedov I.I., Omelyanovsky V.V., Shestakova M.V., Avksentyeva M.V., Ignatieva V.I. Diabetes melli-tus as an economic problem in the Russian Federation. Sakharnyy Diabet. 2016;19(1):30-43. (In Russ).Дедов И.И., Шестакова М.В., Викулова О.К. Эпидемиология сахарного диабета в Российской Федерации: клинико-статистический анализ по данным Федерального регистра сахарного диабета. Сахарный диабет. 2017;20 (1):13-41.Dedov I.I., Shestakova M.V., Vikulova О.К. Epidemiology of diabetes in the Russian Federation: clinical and statistical analysis according to the Federal Register of Diabetes. Sakharnyy Diabet. 2017;20(1):13-41. (In Russ).Дедов И.И., Шестакова М.В., Галстян Г.Р. Распространенность сахарного диабета 2 типа у взрослого населения России (исследование NATION). Сахарный диабет. 2016;19(2):104-112.Dedov I.I., Shestakova M.V., Galstyan G.R. Prevalence of type 2 diabetes in the adult population of Russia (NATION study). Sakharnyy Diabet. 2016;19(2):104-112. (In Russ).Мельниченко Г.А., Яхно Н.Н., Мартынов А.И. и соавт. Диагностика и рациональная терапия болевой диабетической периферической нейропатии. Междисциплинарный консенсус экспертов (РНМОТ, РАЭ, РОИБ). Терапия. 2018;3:12-38.Melnichenko G.A., Yakhno N.N., Martynov A.I., et al. Diagnosis and rational therapy of painful diabetic peripheral neuropathy. Interdisciplinary consensus of experts (РНМОТ, RAE, ROIB). Terapiya. 2018;3:12-38. (In Russ).Храмилин В.Н. Актуальные вопросы ведения пациентов с диабетической полинейропатией. Consilium medicum. 2016;18(9):92-97.Khramilin V.N. Top challenges affecting the management of patients with diabetic polyneuropathy. Consilium medicum. 2016;18(9):92-97. (In Russ).Храмилин В.Н., Андреева В.А., Демидова И.Ю. Комбинированная терапия диабетической полинейропатии: результаты пилотного исследования. Фарматека. 2014;16(289):48-53.KhramiLin V.N., Andreeva V.A., Demidova I .Yu. Combined therapy of diabetic polyneuropathy: results of a pilot study. Pharmateca. 2014;16(289):48-53. (In Russ).Agathos et aL. Effect of a-Lipoic acid on symptoms and quality of Life in patients with painful diabetic neuropathy. Journal of International Medical Research. 2018;46(5):1779-1790.Agathos et aL. Effect of a-Lipoic acid on symptoms and quality of Life in patients with painful diabetic neuropathy. Journal of International Medical Research. 2018;46(5):1779-1790.BouLton AJ.M., ViLeikyte L., Painful Diabetic Neuropathy in CLinicaL Practice, Springer London, 2011. ISBN 978-0-85729-487-6. doi: 10.1007/978-0-85729-488-3_3.BouLton AJ.M., ViLeikyte L., Painful Diabetic Neuropathy in CLinicaL Practice, Springer London, 2011. ISBN 978-0-85729-487-6. doi: 10.1007/978-0-85729-488-3_3.BriL V. et aL. Canadian Diabetes Association CLinicaL Practice GuideLines. Neuropathy. Can J Diabetes. 2013;37:S142-S144.BriL V. et aL. Canadian Diabetes Association CLinicaL Practice GuideLines. Neuropathy. Can J Diabetes. 2013;37:S142-S144.BriL V., EngLand J., FrankLin G.M. et aL. Evidence-based guideLine: Treatment of painfuL diabetic neuropathy. Report of the American Academy of NeuroLogy, the American Association of NeuromuscuLar and ELectrodiagnostic Medicine, and the American Academy of PhysicaL Medicine and RehabiLitation. Neurology. 2011 May 17;76(20):1758-1765.BriL V., EngLand J., FrankLin G.M. et aL. Evidence-based guideLine: Treatment of painfuL diabetic neuropathy. Report of the American Academy of NeuroLogy, the American Association of NeuromuscuLar and ELectrodiagnostic Medicine, and the American Academy of PhysicaL Medicine and RehabiLitation. Neurology. 2011 May 17;76(20):1758-1765.Qakici N., FakkeL T.M., van Neck J.W., Verhagen A.P., Coert J.H. Systematic review of treatments for diabetic peripheraL neuropathy. Diabet Med. 2016 Nov;33(11):1466-1476.Qakici N., FakkeL T.M., van Neck J.W., Verhagen A.P., Coert J.H. Systematic review of treatments for diabetic peripheraL neuropathy. Diabet Med. 2016 Nov;33(11):1466-1476.CaLLaghan B.C., LittLe A.A., FeLdman E.L., Hughes R.A.C. Enhanced gLucose controL for preventing and treating diabetic neuropathy. Cochrane Database of Systematic Reviews. 2012;6:CD007543. doi: 10.1002/14651858.CD007543.pub2.CaLLaghan B.C., LittLe A.A., FeLdman E.L., Hughes R.A.C. Enhanced gLucose controL for preventing and treating diabetic neuropathy. Cochrane Database of Systematic Reviews. 2012;6:CD007543. doi: 10.1002/14651858.CD007543.pub2.DCCT (The Diabetes ControL and CompLications TriaL Research Group). The effect of intensive treatment of diabetes on the deveLopment and progression of Long-term compLications in insuLin-dependent diabetes meLLitus. N Engl J Med. 1993;329:977-986.DCCT (The Diabetes ControL and CompLications TriaL Research Group). The effect of intensive treatment of diabetes on the deveLopment and progression of Long-term compLications in insuLin-dependent diabetes meLLitus. N Engl J Med. 1993;329:977-986.DCCT Research Group: The effect of intensive diabetes therapy on the deveLopment and progression of neuropathy. Ann Int Med. 1995;122:561-568.DCCT Research Group: The effect of intensive diabetes therapy on the deveLopment and progression of neuropathy. Ann Int Med. 1995;122:561-568.Finnerup N.B., AttaL N. et aL. Pharmacotherapy for neuropathic pain in aduLts: a systematic review and meta-anaLysis. Lancet Neurol. 2015:162-73.Finnerup N.B., AttaL N. et aL. Pharmacotherapy for neuropathic pain in aduLts: a systematic review and meta-anaLysis. Lancet Neurol. 2015:162-73.FrankLin G.M., ShetterLy S.M., Cohen J.A., Baxter J., Hamman R.F. Risk factors for distaL symmetric neuropathy in NIDDM. Diabetes Care. 1994;17:1172-1177.FrankLin G.M., ShetterLy S.M., Cohen J.A., Baxter J., Hamman R.F. Risk factors for distaL symmetric neuropathy in NIDDM. Diabetes Care. 1994;17:1172-1177.Fraser DA., Diep L.M., Hovden I.A., NiLsen K.B., Sveen K.A., SeLjefLot I., Hanssen K.F. Diabetes Care. 2012 May;35(5):1095-1097. Epub 2012 Mar 23.Fraser DA., Diep L.M., Hovden I.A., NiLsen K.B., Sveen K.A., SeLjefLot I., Hanssen K.F. Diabetes Care. 2012 May;35(5):1095-1097. Epub 2012 Mar 23.Gerritje S. Mijnhout, Boudewijn J. KoLLen, ALaa ALkhaLaf, Nanno KLeefstra and Henk J.G. BiLo. ALpha Lipoic Acid for Symptomatic PeripheraL Neuropathy in Patients with Diabetes: A MetaAnaLysis of Randomized ControLLed TriaLs. International Journal of Endocrinology. 2012; ArticLe ID 456279. doi:10.1155/2012/456279.Gerritje S. Mijnhout, Boudewijn J. KoLLen, ALaa ALkhaLaf, Nanno KLeefstra and Henk J.G. BiLo. ALpha Lipoic Acid for Symptomatic PeripheraL Neuropathy in Patients with Diabetes: A MetaAnaLysis of Randomized ControLLed TriaLs. International Journal of Endocrinology. 2012; ArticLe ID 456279. doi:10.1155/2012/456279.Gibbons C.H., Freeman R. Treatment-induced neuropathy of diabetes: an acute, iatrogenic compLication of diabetes. Brain. 2015 Jan;138(1):43-52.Gibbons C.H., Freeman R. Treatment-induced neuropathy of diabetes: an acute, iatrogenic compLication of diabetes. Brain. 2015 Jan;138(1):43-52.Gibbons C.H. Treatment-Induced Neuropathy of Diabetes. Curr Diab Rep. 2017 Oct 24;17(12):127.Gibbons C.H. Treatment-Induced Neuropathy of Diabetes. Curr Diab Rep. 2017 Oct 24;17(12):127.Haupt E., Ledermann H., Kopcke W. Benfotiamine in the treatment of diabetic poLyneuropathy-a three-week randomized, controLLed piLot study (BEDIP study). Int J Clin Pharmacol Ther. 2005 Feb;43(2):71-77.Haupt E., Ledermann H., Kopcke W. Benfotiamine in the treatment of diabetic poLyneuropathy-a three-week randomized, controLLed piLot study (BEDIP study). Int J Clin Pharmacol Ther. 2005 Feb;43(2):71-77.Garcia-ALcaLa Н. et aL. Treatment with –Lipoic Acid over 16 Weeks in Type 2 Diabetic Patients with Symptomatic PoLyneuropathy Who Responded to InitiaL 4-Week High-Dose 40. Loading. Journal of Diabetes Research. 2015;ArticLe ID 189857. PubLished onLine 2015 Aug 4. doi: 10.1155/2015/189857.Garcia-ALcaLa Н. et aL. Treatment with –Lipoic Acid over 16 Weeks in Type 2 Diabetic Patients with Symptomatic PoLyneuropathy Who Responded to InitiaL 4-Week High-Dose 40. Loading. Journal of Diabetes Research. 2015;ArticLe ID 189857. PubLished onLine 2015 Aug 4. doi: 10.1155/2015/189857.InternationaL Diabetes Federation CLinicaL Practice Recommendations on the Diabetic Foot. 2017. https//www.idf.org/54-our-activities/222-idf-cLinicaL-practice-recommen-dations-on-the-diabetic-foot.htmL.InternationaL Diabetes Federation CLinicaL Practice Recommendations on the Diabetic Foot. 2017. https//www.idf.org/54-our-activities/222-idf-cLinicaL-practice-recommen-dations-on-the-diabetic-foot.htmL.InternationaL diabetes federation, diabetes atLas, seventh edition, 2017. AvaiLabLe at ttp//www.diabetesatLas.org/.InternationaL diabetes federation, diabetes atLas, seventh edition, 2017. AvaiLabLe at ttp//www.diabetesatLas.org/.Jacobs A.M., Cheng D. Addition of Metanx in pregabaLin partiaL responders for painfuL diabetic neuropathy. Journal of Diabetes Mellitus 2013;3(3):134-138.Jacobs A.M., Cheng D. Addition of Metanx in pregabaLin partiaL responders for painfuL diabetic neuropathy. Journal of Diabetes Mellitus 2013;3(3):134-138.LechLeitner M. et aL. Diabetische Neuropathie. Wiener klinische Wochenschrift. 2016;128(2):73-79.LechLeitner M. et aL. Diabetische Neuropathie. Wiener klinische Wochenschrift. 2016;128(2):73-79.Lee C.C. et aL. PeripheraL Neuropathy and Nerve Dysfunction in IndividuaLs at High Risk for Type 2 Diabetes: The PROMISE Cohort. Diabetes Care. 2015 Feb; dc142585.Lee C.C. et aL. PeripheraL Neuropathy and Nerve Dysfunction in IndividuaLs at High Risk for Type 2 Diabetes: The PROMISE Cohort. Diabetes Care. 2015 Feb; dc142585.Maser R.E., Steenkiste A.R., Dorman J.S.,NieLsen V.K. et aL. EpidemioLogicaL correLates of diabetic neuropathy: report from Pittsburgh EpidemioLogy of Diabetes CompLications Study. 45. Diabetes. 1989;38:1456-1461.Maser R.E., Steenkiste A.R., Dorman J.S.,NieLsen V.K. et aL. EpidemioLogicaL correLates of diabetic neuropathy: report from Pittsburgh EpidemioLogy of Diabetes CompLications Study. Diabetes. 1989;38:1456-1461.Medina-SantiLLan R., MoraLes-Franco G., Espinoza-Raya J., Granados-Soto V., Reyes-Garcia G. Treatment of Diabetic Neuropathic Pain with Gabapentin ALone or Combined with Vitamin B CompLex. PreLiminary ResuLts. Proc. West. Pharmacol. Soc. 2004;47:109-112.Medina-SantiLLan R., MoraLes-Franco G., Espinoza-Raya J., Granados-Soto V., Reyes-Garcia G. Treatment of Diabetic Neuropathic Pain with Gabapentin ALone or Combined with Vitamin B CompLex. PreLiminary ResuLts. Proc. West. Pharmacol. Soc. 2004;47:109-112.Moore R.A. et aL. Gabapentin for chronic neuropathic pain and fibromyaLgia in aduLts. Cochrane Database Syst Rev. 2014 Apr 27;4.Moore R.A. et aL. Gabapentin for chronic neuropathic pain and fibromyaLgia in aduLts. Cochrane Database Syst Rev. 2014 Apr 27;4.Papanas N. & ZiegLer D. Efficacy of a-Lipoic acid in diabetic neuropathy. Expert Opin.Pharmacother. 2014;15(18):2721-2731.Papanas N. & ZiegLer D. Efficacy of a-Lipoic acid in diabetic neuropathy. Expert Opin.Pharmacother. 2014;15(18):2721-2731.Papanas N. and ZiegLer D. Risk Factors and Comorbidities in Diabetic Neuropathy: An Update 2015. Rev Diabet Stud. 2015;12:48-62.Papanas N. and ZiegLer D. Risk Factors and Comorbidities in Diabetic Neuropathy: An Update 2015. Rev Diabet Stud. 2015;12:48-62.PerumbaLath A., Czanner G., Brown E., Cuthbertson DJ., MaLik R.A., ALam U. Neurodiab 2018. 28th ANNUAL MEETING OF THE DIABETIC NEUROPATHY STUDY GROUP OF THE EUROPEAN ASSOCIATION FOR THE STUDY OF DIABETES (EASD). Program and abstract book. The prevaLence of peripheraL neuropathy in prediabetes: a systematic review and metaanaLysis. O36. http//www.neurodiab2018.PerumbaLath A., Czanner G., Brown E., Cuthbertson DJ., MaLik R.A., ALam U. Neurodiab 2018. 28th ANNUAL MEETING OF THE DIABETIC NEUROPATHY STUDY GROUP OF THE EUROPEAN ASSOCIATION FOR THE STUDY OF DIABETES (EASD). Program and abstract book. The prevaLence of peripheraL neuropathy in prediabetes: a systematic review and metaanaLysis. O36. http//www.neurodiab2018.Pop-Busui R. et aL. Diabetic Neuropathy: A Position Statement by the American Diabetes Association. Diabetes Care. 2017;40:136-154.Pop-Busui R. et aL. Diabetic Neuropathy: A Position Statement by the American Diabetes Association. Diabetes Care. 2017;40:136-154.ReLjanovic M., ReicheL G., Rett K., et aL. Treatment of diabetic poLyneuropathy with the antioxidant thioctic acid (aLpha-Lipoic acid): a two year muLticentre randomized doubLe-bLind pLacebo-controLLed triaL (ALADIN II). Free Radic Res. 1999;31:171-179.ReLjanovic M., ReicheL G., Rett K., et aL. Treatment of diabetic poLyneuropathy with the antioxidant thioctic acid (aLpha-Lipoic acid): a two year muLticentre randomized doubLe-bLind pLacebo-controLLed triaL (ALADIN II). Free Radic Res. 1999;31:171-179.Rudroju NeeLima et aL. Comparative Efficacy and Safety of Six Antidepressants and AnticonvuLsants in PainfuL Diabetic Neuropathy: A Network Meta-anaLysis. Pain Physician. 2013;16:E705-E714.Rudroju NeeLima et aL. Comparative Efficacy and Safety of Six Antidepressants and AnticonvuLsants in PainfuL Diabetic Neuropathy: A Network Meta-anaLysis. Pain Physician. 2013;16:E705-E714.Ruhnau KJ., Meissner H.P., Finn J.R. et aL. Effects of 3-week oraL treatment with the antioxidant thioctic acid (aLpha-Lipoic acid) in symptomatic diabetic poLyneuropathy. Diabet Med. 1999;16:1040-1043.Ruhnau KJ., Meissner H.P., Finn J.R. et aL. Effects of 3-week oraL treatment with the antioxidant thioctic acid (aLpha-Lipoic acid) in symptomatic diabetic poLyneuropathy. Diabet Med. 1999;16:1040-1043.Shafina Sachedina, Cory Toth. Association of comorbidities with increasing severity of peripheraL neuropathy in diabetes meLLitus. World J Diabetes. 2013 August 15;4(4):135-144. SingLeton RJ., Smith A.G., Marcus R.L. Exercise as Therapy for Diabetic and Prediabetic Neuropathy. Curr Diab Rep. 2015;15:120. Snedecor SJ., Sudharshan L., CappeLLeri J.C. et aL. Systematic review and meta-anaLysis of pharmacoLogicaL therapies for painfuL diabetic peripheraL neuropathy. Pain Pract. 2014;14:167-84.Shafina Sachedina, Cory Toth. Association of comorbidities with increasing severity of peripheraL neuropathy in diabetes meLLitus. World J Diabetes. 2013 August 15;4(4):135-144. SingLeton RJ., Smith A.G., Marcus R.L. Exercise as Therapy for Diabetic and Prediabetic Neuropathy. Curr Diab Rep. 2015;15:120. Snedecor SJ., Sudharshan L., CappeLLeri J.C. et aL. Systematic review and meta-anaLysis of pharmacoLogicaL therapies for painfuL diabetic peripheraL neuropathy. Pain Pract. 2014;14:167-84.Spijkerman A.M., Dekker J.M., NijpeLs G. et aL. MicrovascuLar compLications at time of diagnosis of type 2 diabetes are simiLar among diabetic patients detected by targeted screening and patients newLy diagnosed in generaL practice: the hoorn screening study. Diabetes Care. 2003 Sep;26(9):2604-8.Spijkerman A.M., Dekker J.M., NijpeLs G. et aL. MicrovascuLar compLications at time of diagnosis of type 2 diabetes are simiLar among diabetic patients detected by targeted screening and patients newLy diagnosed in generaL practice: the hoorn screening study. Diabetes Care. 2003 Sep;26(9):2604-8.Stracke H., Gaus W., Achenbach U., FederLin K., Bretze R.G. Benfotiamine in Diabetic PoLyneuropathy (BENDIP): ResuLts of a Randomised, DoubLe BLind, PLacebo-controLLed CLinicaL Study. Exp Clin Endocrinol Diabetes. 2008;116(10):600-605.Stracke H., Gaus W., Achenbach U., FederLin K., Bretze R.G. Benfotiamine in Diabetic PoLyneuropathy (BENDIP): ResuLts of a Randomised, DoubLe BLind, PLacebo-controLLed CLinicaL Study. Exp Clin Endocrinol Diabetes. 2008;116(10):600-605.Tesfaye S. et aL. Diabetic Neuropathies: Update on Definitions, Diagnostic Criteria, Estimation of Severity, and Treatments. Diabetes Care. 2010;33:2285-2293.Tesfaye S. et aL. Diabetic Neuropathies: Update on Definitions, Diagnostic Criteria, Estimation of Severity, and Treatments. Diabetes Care. 2010;33:2285-2293.Varkonyi et aL. Combination Therapy in Diabetic Neuropathy. Diabetes, Stoffwechsel und Herz. 2016;25:163-170.Varkonyi et aL. Combination Therapy in Diabetic Neuropathy. Diabetes, Stoffwechsel und Herz. 2016;25:163-170.Vinik A.I., CaseLLini C.M. GuideLines in the management of diabetic nerve pain. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy. 2013;6:57-78.Vinik A.I., CaseLLini C.M. GuideLines in the management of diabetic nerve pain. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy. 2013;6:57-78.ZiegLer D., Ametov A., Barinov A. et aL. OraL Treatment With a-Lipoic Acid Improves Symptomatic Diabetic PoLyneuropathy (The SYDNEY 2 triaL). Diabetes Care. 2006;29:2365-2370.ZiegLer D., Ametov A., Barinov A. et aL. OraL Treatment With a-Lipoic Acid Improves Symptomatic Diabetic PoLyneuropathy (The SYDNEY 2 triaL). Diabetes Care. 2006;29:2365-2370.ZiegLer D., HanefeLd M., Ruhnau KJ. et aL. Treatment of symptomatic diabetic peripheraL neuropathy with the anti- oxidant aLpha-Lipoic acid. A 3-week muLticentre randomized controLLed triaL (ALADIN Study). Diabetologia. 1995;38:1425-1433.ZiegLer D., HanefeLd M., Ruhnau KJ. et aL. Treatment of symptomatic diabetic peripheraL neuropathy with the anti- oxidant aLpha-Lipoic acid. A 3-week muLticentre randomized controLLed triaL (ALADIN Study). Diabetologia. 1995;38:1425-1433.ZiegLer D., HanefeLd M., Ruhnau KJ. et aL. Treatment of symptomatic diabetic poLyneuropathy with the antioxidant aLpha-Lipoic acid: a 7-month muLticenter randomized controLLed triaL (ALADIN III Study). ALADIN III Study Group. ALpha-Lipoic Acid in Diabetic Neuropathy. Diabetes Care. 1999;22:1296-1301.ZiegLer D., HanefeLd M., Ruhnau KJ. et aL. Treatment of symptomatic diabetic poLyneuropathy with the antioxidant aLpha-Lipoic acid: a 7-month muLticenter randomized controLLed triaL (ALADIN III Study). ALADIN III Study Group. ALpha-Lipoic Acid in Diabetic Neuropathy. Diabetes Care. 1999;22:1296-1301.ZiegLer D., Nowak H., KempLer P., Varghaa P., Low P.A. Treatment of symptomatic diabetic poLyneuropathy with the antioxidant a-Lipoic acid: a meta-anaLysis. Diabetic Medicine. 2004;21:114-121.ZiegLer D., Nowak H., KempLer P., Varghaa P., Low P.A. Treatment of symptomatic diabetic poLyneuropathy with the antioxidant a-Lipoic acid: a meta-anaLysis. Diabetic Medicine. 2004;21:114-121.ZiegLer D. et aL. Efficacy and safety of antioxidant treatment with a-Lipoic acid over 4 years in diabetic poLyneuropathy: the NATHAN 1 triaL. Diabetes Care. 2011 Sep;34(9):2054-60.ZiegLer D. et aL. Efficacy and safety of antioxidant treatment with a-Lipoic acid over 4 years in diabetic poLyneuropathy: the NATHAN 1 triaL. Diabetes Care. 2011 Sep;34(9):2054-60.ZiegLer D., KeLLer J., Maier С., Pannek J. DDG Praxis empfehLungen. Diabetische Neuropathie. Diabetologie. 2017;12(SuppL 2):S101-S114.ZiegLer D., KeLLer J., Maier С., Pannek J. DDG Praxis empfehLungen. Diabetische Neuropathie. Diabetologie. 2017;12(SuppL 2):S101-S114.ZiegLer D., Low Ph.A., Freeman R., TritschLer H., Vinik A.I. Predictors of improvement and progression of diabetic poLyneuropathy foLLowing treatment with a-Lipoic acid for 4 years in the NATHAN 1 triaL. Journal of Diabetes and Its Complications. 2016;30:350-356.ZiegLer D., Low Ph.A., Freeman R., TritschLer H., Vinik A.I. Predictors of improvement and progression of diabetic poLyneuropathy foLLowing treatment with a-Lipoic acid for 4 years in the NATHAN 1 triaL. Journal of Diabetes and Its Complications. 2016;30:350-356.

The authors declare that there are no conflicts of interest present.